Sudden hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment

World Journal of Gastroenterology

Volumn 13, Issue 40, 2007, Pages 5411-5412

  Elloumi, Héla ^a   Houissa, Fatma ^a   Hadj, Najet Bel ^a   Gargouri, Dalila ^a   Romani, Malika ^a   Kharrat, Jamel ^a   Ghorbel, AbdelJabbar ^a  

^a HABIB THAMEUR HOSPITAL   (Tunisia)

Author keywords

Adverse effects; Hearing loss; Hepatitis C; Interferon; Ribavirin

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; AUDITORY SYSTEM EXAMINATION; AWARENESS; CASE REPORT; DISEASE ASSOCIATION; GENOTYPE; HEARING LOSS; HEPATITIS C; HUMAN; MALE; MEDICAL DECISION MAKING; PATIENT ATTITUDE; PATIENT MONITORING; PHYSICIAN ATTITUDE; RNA ANALYSIS; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 35248892932     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i40.5411     Document Type: Article

References (15)

1. World Health Organization. Weekly Epidemiological Record. No. 49, 10 December 1999; Hepatitis C Fact Sheet No. 164, October 2000. Available from: URL: http://www.who.int/inf-fs/en/fact164.html
2. Habib Ben Khalifa. Epidemiologie Du Virus C En Tunisie: Ou En Sommes Nous? Available from: URL: http://www.stmi.org.tn
3. Triki H, Said N, Ben Salah A, Arrouji A, Ben Ahmed F, Bouguerra A, Hmida S, Dhahri R, Dellagi K. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg 1997; 91: 11-14
4. Djebbi A, Triki H, Bahri O, Cheikh I, Sadraoui A, Ben Ammar A, Dellagi K. Genotypes of hepatitis C virus circulating in Tunisia. Epidemiol Infect 2003; 130: 501-505
5. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36: S3-S20
6. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003; 52: 1784-1787
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
8. Wong VK, Cheong-Lee C, Ford JA, Yoshida EM. Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: outcome after resumption of therapy. World J Gastroenterol 2005; 11: 5392-5393
9. Tunca A, Erbayrak M, Aytac S, Turkay C. Axonal neuropathy and hearing loss associated with alpha interferon treatment in chronic hepatitis B: a case report. Turk J Gastroenterol 2004; 15: 97-99
10. Formann E, Stauber R, Denk DM, Jessner W, Zollner G, Munda-Steindl P, Gangl A, Ferenci P. Sudden hearing loss in patients with chronic hepatitis C treated with pegylated interferon/ribavirin. Am J Gastroenterol 2004; 99: 873-877
11. Cadoni G, Marinelli L, De Santis A, Romito A, Manna R, Ottaviani F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis. J Laryngol Otol 1998; 112: 962-963
12. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26: 112S-121S
13. Kanda Y, Shigeno K, Matsuo H, Yano M, Yamada N, Kumagami H. Interferon-induced sudden hearing loss. Audiology 1995; 34: 98-102
14. Gorur K, Kandemir O, Unal M, Ozcan C. The effect of recombinant interferon alpha treatment on hearing thresholds in patients with chronic viral hepatitis B. Auris Nasus Larynx 2003; 30: 41-44
15. Kanda Y, Shigeno K, Kinoshita N, Nakao K, Yano M, Matsuo H. Sudden hearing loss associated with interferon. Lancet 1994; 343: 1134-1135